Bio-Technopark
In very close proximity to the Swiss Federal Institute of Technology (ETH), the University and Zurich University Hospital, a science park for life science companies and institutions has developed in the last two decades, which has now acquired both national and international significance. On an area of 55,000 m2, the park now hosts 45 companies and many academic institutions representing a healthy mix of young start-ups and global companies as well as university clinics, institutes, and research groups.
Leasing
In the Bio-Technopark, it is possible to rent ultramodern laboratories, offices, and complex infrastructure for research and development purposes. The premises offered include fully-equipped laboratory facilities with communal infrastructure, and individual rental areas in different sizes and locations and with different fit-out standards. The Bio-Technopark is still being developed and gradually fitted out.
Services
The Bio-Technopark promotes the transfer of knowledge and technology, as well as the foundation and building up of life science companies. In addition to advice, coaching, and support for those who are setting up and developing companies and looking for financing, its services include the organization of events that focus on networking, facilitating the exchange of ideas between specialists, and advanced training.
News
Center for Laboratory Medicine St. Gallen is the first laboratory to offer Proclarix® from Proteomedix
Schlieren and St. Gallen, Switzerland, April 2, 2020. The Center for Laboratory Medicine in St. Gallen and Proteomedix, the Swiss cancer diagnostics company, announced today that Proclarix®, a new blood-based test for prostate cancer diagnosis, is made available by the Center for Laboratory Medicine St. Gallen (Zentrum für Labormedizin St. Gallen, ZLM). ”Proclarix is...
Kuros Biosciences reports results for the full year 2019
Schlieren (Zurich), Switzerland, March 26, 2020 – Kuros Biosciences successfully delivered on its targets in 2019, increasing sales of MagnetOs fivefold and confirming its successful transition into a fully-fledged orthobiologics company with scientific, clinical, and commercial excellence in bone regeneration. Kuros raised gross proceeds of CHF 12.5 million from a capital...